GlassScriptPhysician profile
Andrew Taus Perry
NPI 1356902043
$2,510.77
in general payments reported to CMS, 2019-2025
18 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $265 · 2021: $378 · 2022: $499 · 2023: $179 · 2024: $324 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $329.64 | 2020-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $312.11 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $269.00 | 2019-2023 | Verquvo, Belsomra |
| Astrazeneca Pharmaceuticals LP | $252.73 | 2019-2025 | Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.37 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $191.03 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $168.35 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $145.89 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Sunovion Pharmaceuticals INC. | $123.24 | 2019 | |
| Supernus Pharmaceuticals, INC. | $120.79 | 2021 | |
| Exact Sciences Corporation | $81.49 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $57.32 | 2024-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $30.11 | 2019-2023 | |
| Zimmer Biomet Holdings, INC. | $23.49 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $18.73 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $18.40 | 2025 | Zoryve |
| Mylan Specialty L.P. | $15.08 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.